Aptiom regulatory update

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. unit said it submitted an sNDA to FDA for Aptiom eslicarbazepine acetate as monotherapy or adjunctive therapy to treat partial-onset seizures in chil...